Preparation and characterization of solid lipid nanoparticles loaded with frankincense and myrrh oil by Shi, Feng et al.
© 2012 Shi et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2012:7 2033–2043
International Journal of Nanomedicine
Preparation and characterization of solid lipid 
nanoparticles loaded with frankincense  
and myrrh oil
Feng Shi
Ji-Hui Zhao
Ying Liu
Zhi Wang
Yong-Tai Zhang
Nian-Ping Feng
School of Pharmacy, Shanghai 
University of Traditional 
Chinese Medicine, Shanghai, 
People’s Republic of China
Correspondence: Nian-Ping Feng 
Department of Pharmaceutics, School  
of Pharmacy, Shanghai University of  
Traditional Chinese Medicine,  
1200 Cailun Road, Zhangjiang Hi-Tech 
Park, Pudong New District, Shanghai 
201203, People’s Republic of China 
Tel +86 21 5132 2198 
Fax +86 21 5132 2198 
Email npfeng@hotmail.com
Abstract: The aim of the present study was to prepare solid lipid nanoparticles (SLNs) for the 
oral delivery of frankincense and myrrh essential oils (FMO). Aqueous dispersions of SLNs were 
successfully prepared by a high-pressure homogenization method using Compritol 888 ATO as 
the solid lipid and soybean lecithin and Tween 80 as the surfactants. The properties of the SLNs 
such as particle size, zeta potential (ZP), and drug encapsulation efficiency (EE) were inves-
tigated. The morphology of SLNs was observed by transmission electron microscopy (TEM). 
The crystallinity of the formulation was analyzed by differential scanning calorimetry (DSC) 
and X-ray diffraction (XRD). In addition, drug evaporation release and antitumor activity were 
also studied. Round SLNs with a mean size of 113.3 ± 3.6 nm, a ZP of −16.8 ± 0.4 mV , and an 
EE of 80.60% ± 1.11% were obtained. DSC and XRD measurements revealed that less ordered 
structures were formed in the inner cores of the SLN particles. Evaporation loss of the active 
components in FMO could be reduced in the SLNs. Furthermore, the SLN formulation increased 
the antitumor efficacy of FMO in H22-bearing Kunming mice. Hence, the presented SLNs can be 
used as drug carriers for hydrophobic oil drugs extracted from traditional Chinese medicines.
Keywords: solid lipid nanoparticles, frankincense oil, myrrh oil, evaporation release, antitumor 
activity, traditional Chinese medicine
Introduction
Frankincense and myrrh are gum resins obtained from the genera Boswellia and 
C  ommiphora, respectively. Both genera belong to the family Burseraceae, which is 
native to Northeast Africa and the Middle East.1,2 Frankincense and myrrh have been 
used for medical purposes in China and India for thousands of years.3 In traditional 
Chinese medicine, frankincense and myrrh have synergistic effects when used in 
combination (generally in a 1:1 ratio), and the book Compendium of Materia Medica 
introduced the therapeutic characteristics of the combination of frankincense and 
myrrh during the Ming Dynasty. Modern pharmacological research has revealed that 
essential oils are the primary effective components in frankincense and myrrh oil 
(FMO) that exhibit a broad spectrum of biological activities such as antimicrobial, 
anti-inflammatory, and antitumor activities.4–6
However, despite these pharmacological functions, insufficient attention has 
been focused on the side effects of FMO. As with other essential oils, the instability 
and poor water solubility of FMO result in poor oral bioavailability, which limits its 
clinical application.7 The components of FMO are sensitive to light, air, and high 
temperature, and FMO stimulates the gastrointestinal tract, making it unsuitable for 
oral administration. Therefore, a formulation that can overcome the aforementioned 
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problems is highly desired. The conventional method of 
generating the FMO formulation is beta-cyclodextrin (β-CD) 
inclusion. Although this method is inexpensive, it has not 
advanced beyond the empirical stage because the process is 
cumbersome, and the yielded product is unstable and may 
contain organic solvent residue. The rapid development of 
nanodrug delivery systems may support the production of 
essential oil formulations. Several studies have revealed that 
nanostructured lipid carriers and self-microemulsifying drug 
delivery systems enhance the stability and water solubility 
of essential oils.8,9
Solid lipid nanoparticles (SLNs), a new nanoparticle-
based drug-delivery system with particles that range in 
diameter from 10 to 1000 nm, have attracted considerable 
attention. The advantages of SLNs compared to conventional 
drug-delivery systems include improved efficacy, reduced 
toxicity, protection of active compounds, and enhanced 
biocompatibility.10 Moreover, SLNs can be produced on a 
large scale for oral drug delivery.11 Given these features, it 
was hypothesized that SLNs would be an ideal delivery sys-
tem for FMO, protecting it from environmental degradation 
and enhancing its antitumor efficacy. As well as this, a freeze-
drying procedure following entrapment in SLNs could make 
FMO more stable and convenient for oral administration.
Therefore, the aim of the present study was to prepare 
SLNs for the oral delivery of FMO (FMO-SLNs) that are 
capable of improving the stability and antitumor efficacy 
of FMO. It must be emphasized that the method for investi-
gating the drug-encapsulation efficiency (EE) of FMO-SLN 
focuses on specific molecules, and as essential oils such as 
FMO are complex mixtures of numerous molecules, the use 
of one or two indexed components is insufficient for com-
prehensively assessing the EE of FMO-SLNs. Thus, in the 
present study, the fingerprint similarity (FS) between the total 
FMO in SLNs and the entrapped FMO in SLNs (stopped by 
a filter membrane) was determined to evaluate the EE from 
a macroscopic perspective.
Materials and methods
Materials
Compritol 888 ATO® (glyceryl dibehenate/behenate) was 
donated by Gattefossé (Saint-Priest, France). Tween 80® was 
purchased from Sigma Aldritch (St Louis, MO).   Soybean 
lecithin (Lipoid S 100) was purchased from Lipoid GmbH 
(Ludwigshafen, Germany). Frankincense and myrrh were 
purchased from Shanghai Kangqiao Medicine Co, Ltd 
(Shanghai, China). Octyl acetate (OA; purity . 98%) and 
β-elemene (β-E; purity . 98%) were purchased from the 
National Institutes for Food and Drug Control (Beijing, 
China). 5-Fluorouracil (5-FU) was obtained from Shanghai 
Xudong Haipu Pharmaceutical Co, Ltd (Shanghai, China). 
Double-distilled water was obtained through the use of a 
Millipore® Simplicity System (Millipore, Billerica, MA), and 
all organic solvents were of analytical reagent grade.
Animal models
Male Kunming mice of clean grade, weighing 18–22 g, were 
provided by the Laboratory Animal Center of the Shanghai 
University of Traditional Chinese Medicine. All experimental 
procedures were performed in accordance with the approval 
of the Animal Ethical Committee, Shanghai University of 
Traditional Chinese Medicine. The animals were kept in an 
agreeable environment for at least 1 week before the start 
of the study.
Extraction of FMO
FMO was extracted using a distillation method.12   Eighteen kg of 
powdered frankincense and myrrh (9 kg each) were   distilled 
in a steam apparatus with an aqueous-phase recycling   system 
for 7 hours. The obtained FMO was dried over sodium sul-
fate and used as the basic material. FMO was stored at 4°C 
until use.
gas chromatography spectrometry 
analysis (gC)
FMO was analyzed on an Agilent 7890A GC system (Agilent 
Technologies, Santa Clara, CA) coupled with a flame ioniza-
tion detector and a split–splitless injector. An Agilent 19091-
413 HP-5 capillary column (30 m × 0.32 mm × 0.25 µm) was 
used. The temperature of the injector and detector was 250°C. 
The speed of the carrier gas (nitrogen) was 2 mL/min. The 
temperature was set to increase from 60°C to 160°C at a rate 
of 5°C/minute and from 160°C to 300°C at a rate of 10°C/
minute; the analyte was then isothermally held for 2 minutes at 
300°C. One microliter was injected in the splitless model.
Preparation of FMO-SLNs
FMO-SLNs were prepared by high-pressure   homogenization.13 
In brief, the lipid phase, consisting of Compritol 888 ATO 
(3% w/w) and FMO (2% w/w), was heated to 5°C–10°C 
above the melting point of Compritol 888 ATO. The aque-
ous phase containing a mixture of surfactants (soybean 
lecithin, 2% w/w and Tween 80, 2% w/w) in double-distilled 
water was s  imultaneously prepared at the same temperature. 
A pre-emulsion was obtained by adding the aqueous phase to 
the lipid phase through a constant flow pump under stirring 
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at 800 rpm for 30 minutes at a temperature above the melting 
temperature. The hot pre-emulsion was further passed through 
a high-pressure homogenizer (NS1001L; GEA, Parma, Italy) 
at 800 bar for six cycles, and the FMO-SLNs were formed after 
cooling the mixture to room temperature in an ice bath.14
Freeze-drying of FMO-SLNs
Mannitol (10%) was used as the cryoprotecting agent, and 
FMO-SLNs in suspension were frozen in a deep freezer (Christ 
Epsilon 2–4 LSC, Martin Christ Gefriertrocknungsanlagen 
GmbH, Osterode am Harz, Germany) according to the freeze 
curve shown in Figure 1. The FMO-SLN powder was then 
obtained and stored at 4°C for DSC and XRD analysis.
Characterization of FMO-SLNs
Particle size and ZP
The size and ZP of FMO-SLNs were measured using a Nano 
ZS90 Zetasizer (Malvern Instruments Ltd,   Worcestershire, UK).
EE and LC
Free FMO (nonentrapped in the FMO-SLNs) was separated 
by an ultrafiltration method.15 OA (21.06% in FMO) and β-E 
(2.58% in FMO) were selected as the indexed components. 
Centrifugal filter tubes (molecular weight cut-off = 10 kDa, 
Nanosep®; Pall Corporation, Port Washington, NY) were used 
to determine the EE. After a suitable dilution, FMO-SLNs 
(0.5 mL) were placed in the upper chamber of a centrifugal 
filter tube and then centrifuged at 5000 rpm for 15 minutes. 
The separated part collected at the bottom of the tube was sub-
jected to GC analysis to determine the OA and β-E content. 
The total drug content in FMO-SLNs was determined after 
extraction with dehydrated alcohol in an ultrasonic bath. Drug 
loading capacity was presented as percent entrapped drug to 
lipid ratio. Encapsulation efficiency could be calculated by 
the following equations:
EE (%) = (EEOA + EEβ-E)/2,
EEOA (%) = (WTotal OA − WFree OA)/WTotal OA, and
EEβ-E (%) = (WTotal β-E − WFree β-E)/WTotal β-E
where WTotal OA and WTotal β-E are the weights of OA and β-E 
in SLNs, respectively, and WFree OA and WFree β-E are the mean 
weights of untrapped OA and β-E, respectively.
FMO is composed of hundreds, or even thousands, of 
components with different molecular structures. The compo-
sition of FMO is so complex that the use of only two indexed 
components did not facilitate comprehensive assessment 
of the EE of FMO-SLNs. Thus, the FS between the total 
FMO in SLNs and the entrapped FMO in SLNs (stopped 
by the filter membrane) was determined to evaluate the EE 
from a macroscopic point of view. The fingerprint of FMO 
was obtained using the established GC method mentioned 
in the section discussing gas chromatography spectrometry 
analysis, and the method of operation is shown in Figure 2.
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Figure 1 Freeze-drying curves of FMO-SLNs.
Abbreviation: FMO-SLNs, frankincense and myrrh oil–solid lipid nanoparticles.
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TEM
The morphology of FMO-SLNs was observed using a 
transmission scanning microscope (JEM-1230; JEOL, Tokyo, 
Japan). After a suitable dilution was created, samples were 
placed on a film-coated copper grid. Thereafter, a drop of  2% 
phosphotungstic acid was added to the film and allowed to 
dry for 10 minutes before observation.
DSC
DSC was performed using a differential scanning calorimeter 
(Shimadzu DSC-60; Shimadzu Corporation, Kyoto, Japan). 
A heating rate of 10°C/minute was used, and the temperature 
range was 20°C–100°C. An empty aluminum pan was used 
for reference.
XRD
Crystalline structures of the FMO-SLN powder were assessed 
with an X-ray diffractometer (Rigaku Corporation, Tokyo, 
Japan). A Cu-Ka radiation source was used, and samples 
were scanned over a 2θ range of 2°–50° with a scanning 
rate of 5°/minute.
In vitro evaporation release
To assess the chemical stability of components from unformu-
lated and formulated FMO, samples were placed in open vials 
and stored at 35°C for 6 days. During this time, essential oil was 
extracted from the samples by immersing them in dehydrated 
alcohol for 30 minutes in an ultrasonic bath and the selected 
components were analyzed using the established GC method. 
Three groups were used: unformulated FMO, FMO-β-CD, 
and FMO-SLN. FMO-β-CD comprised the β-CD inclusion 
compounds of FMO. FMO-β-CD was prepared using a 
  coprecipitation method at a β-CD/FMO molar ratio of 3:1.16
In vivo antitumor activity
H22-bearing Kunming mice were used as a model to assess 
the in vivo antitumor activity of FMO.17,18 H22 cells were 
injected and incubated in the abdominal cavity of mice 
for 6–8 days before they were collected and resuspended 
in PBS. The collected H22 cells (2 × 106/mL) were then 
inoculated subcutaneously into the right forelimb of 
each mouse at a concentration of 0.2 mL. After injec-
tion, the H22-bearing mice were randomly divided into 
six groups (ten mice/group) that were administered one 
of the following treatments: saline (control group), 5-FU 
(reference drug), FMO suspension (prepared with 5% 
Tween 80), FMO-β-CD, blank SLN, or FMO-SLN. 5-FU 
was administered via intraperitoneal injection once every 
2 days at a dose of 25 mg/kg body weight. All other drugs 
were administered orally for 10 consecutive days (saline, 
0.2 mL/mouse; FMO suspension, FMO-β-CD, blank 
SLN, and FMO-SLN, 100 mg/kg body weight). After 
10 days, the mice were killed, and tumors, spleens, and 
thymi were excised. The tumor growth inhibition rate was 
calculated using the following formula: tumor inhibitory 
rate (%) = (C − T)/C × 100%, where “C” and “T” are the 
average tumor weights in the control and test groups, 
respectively. The spleen and thymus indices were calcu-
lated as follows: spleen/thymus index = WS/T/WM, where 
WS/T is the weight of the spleen or thymus and WM is the 
weight of the mouse.
Statistical analysis
Data are expressed as the mean ± standard deviation and 
analyzed using one-way ANOVA. P-values less than 0.05 
were considered significant.
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Figure 2 Schematic diagram for evaluation of the EE of FMO-SLNs.
Abbreviations: EE, encapsulation efficiency; FMO-SLNs, frankincense and myrrh oil–solid lipid nanoparticles.
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Results and discussion
Extraction and gC analysis
A green essential oil (FMO) was obtained at a good yield of 
0.83% by distillation. The established gas chromatograms 
are shown in Figure 3, which indicates that the selected 
indexed components (from peaks 1 to 6) could be sepa-
rated under the GC condition, and that the pharmaceutical 
adjuvants (  including Compritol 888 ATO, Tween 80, and 
soybean   lecithin) did not influence the analysis. The gas 
chromatograms of FMO revealed that FMO is a complex 
mixture of organic compounds. Among the marked peaks, 
peaks 1 and 2 correspond to OA and β-E, respectively. OA 
is present at the highest concentration (21.06%) in FMO, 
and β-E (2.58%) exerts a favorable antitumor activity;19–21 
therefore, these compounds were chosen as the indexed 
components. Peaks 1 to 6 were used to assess the in vitro 
evaporation release of unformulated and formulated FMO.
Preparation of FMO-SLNs
Production techniques for SLNs include high-pressure 
homogenization,22 microemulsion,23 an ultrasound-based 
method,24 and solvent emulsification/evaporation.25,26 
In the present study, SLNs were prepared by high-pressure 
homogenization. High-pressure homogenization is a reliable 
and powerful technique for the preparation of SLNs, and it has 
been utilized on a large scale in the pharmaceutical industry. 
In our preliminary study, FMO was found to have high solu-
bility in different lipids, such as Compritol 888 ATO, Precirol 
ATO 5, glycerin monostearate, and stearin. However, a high EE 
was obtained using Compritol 888 ATO as the lipid. A mixture 
of soybean lecithin and Tween 80 was used as the surfactant. 
Other details of the SLN formulations are given in Table 1.
Characterization of FMO-SLNs
Figure 4A shows the typical particle size distribution of 
FMO-SLNs. As revealed in this figure, FMO-SLNs were 
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Figure 3 gC of a standard sample (A), FMO-SLN (B), and blank SLN (C); peaks 1 and 2 correspond to OA and β-E, respectively.
Abbreviations: FMO-SLNs, frankincense and myrrh oil–solid lipid nanoparticles; GC, gas chromatography; OA, octyl acetate; β-E, β-elemene.
Table 1 Sample composition (%) of FMO-SLNs (w/w)
Formulation Compritol 
888 ATO
FMO Soybean  
lecithin
Tween 80 Water
SLN 3 2 2.5 2.5 90
Abbreviation: FMO-SLNs, frankincense and myrrh oil–solid lipid nanoparticles.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2037
Solid lipid nanoparticles with frankincense and myrrh oilInternational Journal of Nanomedicine 2012:7
0
0.1 11 0 100 1000 10000
5
10
15
20
I
n
t
e
n
s
i
t
y
 
(
%
)
Size (d.nm)
Size distribution by intensity
0
100000
200000
300000
400000
200 100 0 −100 −200
T
o
t
a
l
 
c
o
u
n
t
s
Zeta potential (mV)
Zeta potential distribution
A
B
Figure 4 Particle size (A) and ZP (B) of FMO-SLNs.
Abbreviations: FMO-SLNs, frankincense and myrrh oil–solid lipid nanoparticles; ZP, zeta potential.
Table 2 EE and LC of SLNs (n = 3)
SLN EEOA (%) EEβ-E (%) EE (%) LC (%) FS (%)
NO 1 81.8 80.2 81.00 54.0 98.93
NO 2 83.6 75.1 79.35 52.9 98.03
NO 3 84.3 78.6 81.45 54.3 99.09
Mean 83.23 ± 1.29 77.97 ± 2.61 80.60 ± 1.11 53.73 ± 0.74 98.68 ± 0.57
Abbreviations: EE, encapsulation efficiency; FS, fingerprint similarity; LC, loading capacity; OA, octyl acetate; SLNs, solid lipid nanoparticles; β-E, β-elemene.
A
100 nm
100 nm
B
Figure 5 TEM images of the blank SLNs (A) and FMO-SLNs (B).
Abbreviations: FMO-SLNs, frankincense and myrrh oil–solid lipid nanoparticles; TEM, transmission electron microscopy.
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found to be nanometric and unimodal with a relatively narrow 
size distribution that ranged from 43.8 to 219.5 nm. The 
average diameter was 113.3 ± 3.6 nm, and the polydispersity 
index value was 0.25. ZP is also an important surface 
characteristic of SLNs, and the measurement of ZP allows 
predictions of the storage stability of SLNs.27 As revealed 
in Figure 4B, the FMO-SLNs possessed a high ZP with the 
value of −16.8 ± 0.4 mV , indicating that the surface of the 
FMO-SLNs was negatively charged.
EE is a very important characteristic for judging the 
quality of SLNs. Generally, the methods of assessing 
EE include ultracentrifugation,28 Sephadex minicolumn 
centrifugation,29 dialysis,30 and the ultrafiltration method 
used in the present study. As mentioned in the section on 
extraction and GC analysis, FMO is a complex mixture 
of abundant compounds. Therefore, two components 
were selected as indexed components to evaluate the EE 
from a microscopic point of view, and the FS between the 
total FMO in SLNs and the entrapped FMO in SLNs was 
determined to evaluate the EE from a macroscopic point of 
view. As is shown in Table 2, a high incorporation capacity 
of SLNs was observed because of the high lipophilicity of 
FMO and its good compatibility with Compritol 888 ATO. 
The FS was 98.68% ± 0.57%, indicating that the most 
abundant components were entrapped by the SLNs. The 
results of the present study confirm those of previous work, 
indicating that hydrophobic drugs could be incorporated 
well into lipid carriers with high EE.31
The morphologies of the blank SLNs and FMO-SLNs 
were observed by TEM. As shown in Figure 5, most of the 
particles were round and uniform in size. No significant 
difference was found between the blank SLNs and 
FMO-SLNs.
As has been reported previously,32,33 DSC can be used 
to determine thermodynamic variations related to mor-
phological changes, because different lipid modifications 
possess different melting points and melting enthalpies. In 
the present study, DSC was performed to investigate the 
melting and crystallization behavior of the lipid matrices to 
detect whether these characteristics were changed by SLN 
preparation. As shown in Figure 6, the bulk lipid (Compritol 
888 ATO) displayed a melting point of 75°C. The physical 
mixture and SLN heating curves differed distinctly from 
those of the bulk lipid, and shifts of the melting point of 
the physical mixture and SLNs to 68.3°C and 70.9°C, 
respectively, were observed. The reduction of the melting 
point of the physical mixture was likely caused by the low-
boiling-point components in FMO. Table 3 presents the 
melting points, enthalpy, and crystallinity of the samples. 
The enthalpy and crystallinity of FMO-SLNs were lower 
than those of the initial lipid, indicating an increased num-
ber of lattice defects in FMO-SLNs.34 The results indicate 
that the perfect crystal structure of Compritol 888 ATO was 
changed by SLN preparation, and a new less-ordered phase 
was formed.
As a further microstructure investigation of FMO-
SLNs, XRD was performed to confirm the findings 
obtained by DSC. The X-ray patterns of Compritol 
Temperature (°C)
A
B
C
Endotherm 
02 04 06 08 01 00 120
Figure 6 DSC curves of (A) Compritol 888 ATO, (B) physical mixture, and (C) FMO-SLNs.
Abbreviations: DSC, differential scanning calorimetry; FMO-SLNs, frankincense and myrrh oil–solid lipid nanoparticles.
Table 3 Melting points, enthalpy, and crystallinity of each sample
Samples Melting points  
(°C)
Enthalpy  
(J/g)
Crystallinity   
(%)
Lipid 75.0 130.7 100.0
Physical mixture 68.3 138.4 105.9
FMO-SLNs 70.9 27.2 20.8
Abbreviation: FMO-SLNs, frankincense and myrrh oil–solid lipid nanoparticles.
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888 ATO, mannitol, and FMO-SLNs are shown in F  igure 7. 
As indicated in   Figure 7A, the bulk Compritol 888 ATO 
displayed three peaks at positions 2θ = 4.16°, 21.16°, 
and 23.30°, while Figure 7C shows that the peaks at 
2θ = 4.16° and 21.16° disappeared. In Figure 7C two 
blunt peaks appeared that were likely influenced by the 
cryoprotectant (mannitol), which has a high degree of 
crystallinity (  Figure 7B). From these results, it was con-
firmed that Compritol 888 ATO exhibited a less-ordered 
structure in SLNs.
In vitro evaporation release
Generally, essential oils are unstable when exposed to air, 
light, and high temperature, which may result in the rapid 
evaporation and degradation of some active components 
and further lead to a dramatic decrease in activity.35 Several 
studies have demonstrated that the incorporation of essen-
tial oils into SLNs helps to increase their stability.36,37 To 
investigate the capability of SLNs to prevent the rapid 
evaporation of FMO, six components that possess dif-
ferent boiling points according to the established GC 
spectrum were chosen as the indexed components. β-CD 
inclusion is the most common technique to incorporate 
essential oils, and thus, in the present study, the evapora-
tion release behavior of FMO-β-CD was determined as 
a control. The data for the in vitro evaporation release 
of unformulated FMO, FMO-β-CD, and FMO-SLNs are 
presented in Table 4. Table 4A clearly shows the rapid 
evaporation loss of all six selected components from the 
initial FMO, with evaporation beginning on the second day 
with large losses of more than 50% seen after 6 days of 
storage (excluding component 4). Compared with the initial 
FMO, FMO-β-CD (Table 4B) and FMO-SLN (Table 4C) 
exhibited a considerable decrease in evaporation loss, and 
no component exhibited an evaporation loss exceeding 50% 
after 6 days of storage, indicating that both β-CD inclusion 
and SLN incorporation can prevent the evaporation loss 
of components in FMO.
In vivo antitumor activity
H22 tumor-bearing mice were used as an animal model to 
assess whether FMO-SLNs exhibit antitumor activity. As 
shown in Table 5, neither saline nor blank SLN had any 
measurable effect on tumor growth, indicating that the SLN 
2-theta (°) 
B
A
C
01 02 0 40 30 50
Figure 7 X-ray spectra of (A) Compritol 888 ATO, (B) mannitol, and (C) FMO-SLNs.
Abbreviation: FMO-SLNs, frankincense and myrrh oil–solid lipid nanoparticles.
Table 4 Evaporation release of components
Percent loss (%) No 1 No 2 No 3 No 4 No 5 No 6
A. Initial FMO (n = 3)
Day 1 0 0 0 0 0 0
Day 2 12.22 12.51 13.39 5.15 28.24 48.96
Day 3 19.99 18.58 18.13 18.48 33.03 55.05
Day 4 26.28 25.31 25.65 23.13 39.05 57.78
Day 5 38.56 37.28 36.82 34.17 48.5 63.98
Day 6 50.92 50.07 50.01 46.1 58.08 71.09
B. FMO-β-CD (n = 3)
Day 1 0 0 0 0 0 0
Day 2 −3.13 −1.64 0.43 −4.9 −0.07 2.91
Day 3 0.9 4.27 10.01 −0.29 6.54 2.58
Day 4 13.98 20.05 29.71 28.27 36.05 29.47
Day 5 17.44 21.37 31.63 26.44 41.13 31.65
Day 6 18.74 22.95 33.87 27.69 42.59 34.67
C. FMO-SLNs (n = 3)
Day 1 0 0 0 0 0 0
Day 2 8.21 6.69 4.54 7.16 7.31 4.34
Day 3 19.9 13.53 11.15 15.6 15.13 8.55
Day 4 28.41 20.73 17.39 18.68 19.57 11.59
Day 5 37.57 24.6 21.46 23.87 21.16 13.88
Day 6 44.47 30.93 22.02 26.14 26.16 14.73
Abbreviation: FMO-SLNs, frankincense and myrrh oil–solid lipid nanoparticles.
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Table 5 In vivo antitumor effects in H22-bearing mice (n = 10)
Drug groups Mice body weight (g)  Tumor weight (g) Inhibition rate (%)
Before study After study
Saline 19.84 ± 1.21 30.39 ± 3.24 1.88 ± 0.21 –
5-FU (25 mg/kg) 19.17 ± 1.13 24.47 ± 2.85 0.59 ± 0.17** 68.55
Blank SLN 19.42 ± 1.36 30.94 ± 4.03 1.81 ± 0.22 3.68
FMO (100 mg/kg) 20.03 ± 1.55 25.13 ± 2.31 1.26 ± 0.24** 32.94
β-CD (100 mg/kg) 19.38 ± 0.99 26.11 ± 2.50 1.22 ± 0.16** 34.8
SLN (100 mg/kg) 19.29 ± 1.37 25.23 ± 3.18 1.06 ± 0.15**,# 43.66
Notes: FMO-SLNs, frankincense and myrrh oil–solid lipid nanoparticles. **P , 0.01 vs saline control group;  #P , 0.05 vs FMO suspension group, β-CD group, and 
FMO-β-CD group at 100 mg/kg body weight.
Abbreviation: FMO-SLNs, frankincense and myrrh oil–solid lipid nanoparticles.
vehicle had no influence on antitumor activity. Compared 
with the findings for the saline group, significant antitumor 
effects (P , 0.01) were observed for the FMO suspension, 
FMO-β-CD, and FMO-SLNs. The tumors in these three 
groups were considerably smaller than those in the saline 
group. The inhibition rates of the FMO suspension, FMO-
β-CD, and FMO-SLNs (at a concentration of 100 mg/kg) 
were 31.23%, 34.81%, and 43.66%, respectively. These 
results indicate that the inhibition rate of FMO-β-CD against 
tumor growth was similar to that of the FMO suspension 
(P . 0.05), and that the slight enhancement of the inhibi-
tion rate may be attributable to the increased dissolution of 
FMO by β-CD inclusion. These findings also suggest that 
the antitumor efficacy of the FMO-SLNs was significantly 
higher (P , 0.05) than that of the FMO suspension and 
FMO-β-CD at the same dosage. These results confirmed 
that SLNs represent a better delivery system for antitumor 
therapy.
Changes in the body weight of H22-bearing mice over 
the course of the study are also presented in Table 5. The 
weight of the mice in the saline and blank SLN groups 
increased rapidly, which may have been caused by tumor 
growth. The rates of the weight increase in the 5-FU and 
FMO-SLN groups were lower than those in the saline 
group.
The spleen and thymus are the two primary immune 
organs related to antitumor activity.38 As shown in Figure 8, 
the 5-FU group exhibited significant reductions (P , 0.05) 
in both the spleen and thymus indices as compared to 
the saline group. Slight enhancements of these indices 
were observed in the FMO suspension, FMO-β-CD, and 
FMO-SLN groups, indicating that FMO could enhance 
the immune response in tumor-bearing mice. The results 
confirmed the previous findings that traditional Chinese 
medicines can exert antitumor effects on the immune 
system.39
Numerous investigations have shown that SLNs can 
increase the antitumor efficacy of drugs while reducing 
their systemic side effects.40 This may be due to the 
controlled release behavior and targetable distribution of 
SLNs. A future study will focus on the organ distribution 
of FMO-SLNs.
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Conclusion
In this study, FMO-SLNs were successfully prepared by 
high-pressure homogenization. Compritol 888 ATO showed 
reasonable FMO solubilization capacity. The poorly water-
soluble drug FMO was efficiently encapsulated into the 
nanoparticles. Particles prepared under proper formulation 
conditions were spherical with diameters of ,220 nm. 
A high EE was obtained using the described method. 
Physicochemical characterization revealed that efficiently 
prepared SLNs encapsulated the drug. The drug evaporation 
release study showed that SLN incorporation could prevent 
the evaporation loss of FMO components to a desirable 
degree. Furthermore, FMO-SLNs possess significantly higher 
antitumor efficacy. Hence, the developed SLNs can be used to 
increase the stability and/or to improve the in vivo antitumor 
efficacy of FMO. However, further studies should focus on 
the absorption and distribution of the FMO-SLNs.
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